| ERA-EDTA Congress 2011: Late Breaking Clinical Trials II - PR Newswire (press release) |
|
|
PR Newswire (press release) Whether it also has a favourable effect on renal disease progression was another of the issues addressed by the SHARP study [abstract no. 2509]. In the ezetimibe/simvastatin group, fewer patients reached the end point "end stage renal disease", |